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Abstract 21 
Zika virus (ZIKV) envelope (E) protein is the major target of neutralizing antibodies in 22 
infected host, and thus represents a candidate of interest for vaccine design. 23 
However, a major concern in the development of vaccines against ZIKV and the 24 
related dengue virus is the induction of cross-reactive poorly neutralizing antibodies 25 
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that can cause antibody-dependent enhancement (ADE) of infection. This risk 26 
necessitates particular care in vaccine design. Specifically, the engineered 27 
immunogens should have their cross-reactive epitopes masked, and they should be 28 
optimized for eliciting virus-specific strongly neutralizing antibodies upon vaccination. 29 
Here, we developed ZIKV subunit- and virus-like particle (VLP)-based vaccines 30 
displaying E in its wild type form, or E locked in a covalently linked dimeric (cvD) 31 
conformation to enhance the exposure of E dimers to the immune system. 32 
Compared with their wild-type derivatives, cvD immunogens elicited antibody with 33 
higher capacity of neutralizing virus infection of cultured cells. More importantly, 34 
these immunogens protected animals from lethal challenge with both the African and 35 
Asian lineages of ZIKV, impairing virus dissemination to brain and sexual organs. 36 
Moreover, the locked conformation of E reduced the exposure of epitopes 37 
recognized by cross-reactive antibodies and therefore showed a lower potential to 38 
induce ADE in vitro. Our data demonstrated a higher efficacy of the VLPs in 39 
comparison with the soluble dimer and support VLP-cvD as a promising ZIKV 40 
vaccine. 41 
 42 
Author Summary 43 
Infection with Zika virus (ZIKV) leads to the production by host of antibodies that 44 
target the viral surface envelope (E) protein. A subset of these antibodies can inhibit 45 
virus infection, thus making E as a suitable candidate for the development of vaccine 46 
against the virus. However, the anti-ZIKV E antibodies can cross-react with the E 47 
protein of the related dengue virus on account of the high level of similarity exhibited 48 
by the two viral proteins.  Such a scenario may lead to severe dengue disease. 49 
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Therefore, the design of a ZIKV vaccine requires particular care. Here, we tested two 50 
candidate vaccines containing a recombinant form of the ZIKV E protein that is 51 
forced in a covalently stable dimeric conformation (cvD). They were generated with 52 
an explicit aim to reduce the exposure of the cross-reactive epitopes. One vaccine is 53 
composed of a soluble form of the E protein (sE-cvD), the other is a more complex 54 
virus-like particle (VLP-cvD). We used the two candidate vaccines to immunize mice 55 
and later infected with ZIKV. The animals produced high level of inhibitory antibodies 56 
and were protected from the infection. The VLP-cvD was the most effective and we 57 
believe it represents a promising ZIKV vaccine candidate. 58 
 59 
Introduction 60 
For decades Zika virus (ZIKV) was largely ignored as a human pathogen but the 61 
recent epidemic in South America has brought to light neurological complications 62 
(i.e. Guillain-Barré syndrome)(1) and congenital Zika syndrome (i.e. microcephaly 63 
and other malformations)(2) making ZIKV a public health threat in affected countries. 64 
ZIKV infection occurs mainly via mosquito bite but its persistence in bodily fluids like 65 
semen allows sexual transmission (3). There is currently no vaccine or treatment 66 
available, making their development a priority in ZIKV research. 67 
 68 
Current approaches to vaccine development include purified inactivated virus (4), 69 
DNA/RNA/vector-based vaccines encoding structural proteins (5-10) and purified 70 
viral-like particles (VLPs) (11, 12) or protein subunits (13, 14). Some of these 71 
candidates are currently undergoing phase 1 of clinical trial but the design of a 72 
successful ZIKV vaccine is complicated by the close relation of ZIKV with other 73 
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flaviviruses and especially dengue virus (DENV), also transmitted by Aedes 74 
mosquito vectors and overlapping across many areas.  75 
 76 
ZIKV genome, like other members of the Flaviviridae family, is composed of a 77 
positive strand RNA encoding a single polyprotein that is cleaved into structural 78 
(capsid, precursor-membrane and envelope) and non-structural proteins (NS1, NS2, 79 
NS3, NS4 and NS5). The envelope (E) glycoprotein, with its three domains (DI, DII 80 
and DIII), is the main target of the host immune response (15). During the initial 81 
stages of flavivirus genesis, the E protein is associated with the precursor-membrane 82 
protein (prM) and assumes a trimeric conformation; only during the passage in the 83 
trans-Golgi network, where the viral particle encounters an acidic environment, the 84 
trimers dissociate to re-assemble as dimers (16). This new conformation is 85 
necessary to allow furin-mediated cleavage of prM into pr and M generating a 86 
mature E dimer (17). Once released in the extracellular environment, pr dissociates 87 
and the particle becomes infectious. During infection, the low pH of the endosome 88 
triggers a new conformational modification that mediates fusion of viral and 89 
endosomal membranes (18). However, the particle maturation process is often 90 
incomplete releasing a viral progeny partially displaying E protein in trimers 91 
containing prM. In addition, E protein is in continuous dynamic motion, a 92 
phenomenon called “virus breathing” that is strain- and temperature-dependent (19). 93 
These two factors - incomplete maturation and viral breathing - have important 94 
consequences on epitope accessibility. At its tip, DII harbours the fusion loop (FL) 95 
represented by an amino acid sequence that is highly conserved among flaviviruses. 96 
FL is masked by DI and DIII when E protein on the virion is in a dimeric form but 97 
becomes exposed upon re-arrangement of E in the acidic endosome following cell 98 
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entry. Epitopes located on DI/DII, especially in the FL region (FLE), are immuno-99 
dominant but recognized by cross-reactive and poorly neutralizing antibodies (20, 100 
21). This class of antibodies can be responsible for antibody-dependent 101 
enhancement (ADE) of infection where antibody-bound virus particles are 102 
endocytosed via the Fcγ receptor, leading to a more severe infection (22). Antibodies 103 
to prM also contribute to ADE (22). 104 
In addition, the most potent neutralizing antibodies often recognize complex 105 
quaternary epitopes than bind to multiple adjacent E proteins, epitopes that are 106 
available only when the E protein is assembled in a viral particle and therefore could 107 
not be elicited upon immunization with subunits (23). Recently, a new class of 108 
quaternary epitopes, called the Envelope Dimer Epitopes (EDE), have been 109 
described (24). EDE epitopes are displayed when the E proteins form a head-to-tail 110 
dimeric conformation. Highly neutralizing antibodies recognizing EDE were 111 
discovered in the sera of DENV-infected patients but interestingly, they were also 112 
shown to efficiently neutralize ZIKV, both in in vitro and in in vivo experiments (25-113 
27). Upon binding to pre-fusion E dimers, these antibodies can prevent the transition 114 
of E to a trimeric form and consequently abrogate membrane fusion and infection.  115 
Here, we aimed to develop antigens for ZIKV vaccination that can drive the immune 116 
response preferentially against quaternary/complex epitopes, to increase the 117 
neutralizing potential. Our recent study demonstrated that the introduction of a 118 
disulphide bridge by A264C substitution can stabilize E in a covalent dimer (cvD) 119 
conformation (28). This structure reduces the exposure of the unwanted FLE in 120 
favour of EDE. We generated cvD forms of a soluble E (sE-cvD) and a virus-like 121 
particle (VLP-cvD). The latter is expected to present E predominantly in form of 122 
dimers, conferring a smooth surface to the particles. Vaccination of mice with these 123 
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antigens afforded full protection from lethal ZIKV challenge. Moreover, in comparison 124 
to their WT counterparts, the cvD immunogens elicited antibodies that exhibited 125 
lower in vitro ADE of DENV, yellow fever virus (YFV) and West Nile virus (WNV). 126 
Our data confirmed the potential of cvD mutation in generating an immune response 127 
against neutralizing conformational epitopes, and further identified VLP-cvD as the 128 
most promising candidate of the two cvD derivatives tested. 129 
 130 
Results 131 
Design, expression and purification of E covalent dimer-based vaccines: We 132 
focused on designing antigens that would elicit antibodies to the complex quaternary 133 
epitopes that span two or more ZIKV E molecules. Immunogens based on EDE have 134 
a great potential, but a stable dimeric conformation of E is not easy to achieve. For 135 
this reason, we used a strategy of generating a covalently stable dimeric form by 136 
introducing Ala to Cys mutation in DII (A264C) of E as described previously (28). The 137 
stable dimeric E generated is thus expected to enhance exposure of EDE and 138 
reduce presentation of the unwanted immune-dominant FL region in DII to the 139 
immune system. 140 
We generated a V5 epitope-tagged soluble ZIKV E (sE; i.e. E lacking its stem and 141 
membrane anchor domains) in its wild-type form (sE-WT), and in the form of a 142 
covalently stabilised dimer (sE-cvD) containing the A264C mutation (Fig 1A) (28). In 143 
addition, we also generated wild type (WT) and cvD forms of ZIKV virus-like particles 144 
(VLPs) using plasmid constructs encoding the capsid anchor region (Ca) followed by 145 
the full-length prM and E (Fig 1C). These proteins were produced by transient 146 
transfection of Expi293F cells with the relevant constructs and subsequently purified 147 
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from the cell medium as described in Methods. The purified sE proteins were 148 
analysed in SDS-PAGE gel under reducing and non-reducing conditions (Fig 1B). As 149 
expected, the sE-WT was visible exclusively in the monomeric form, with an 150 
apparent molecular weight of ~50 kDa, while sE-cvD under non-reducing conditions 151 
had an apparent molecular weight corresponding to a dimer (~110 kDa) that could 152 
be reduced to a monomer upon incubation with DTT. A small amount of sE-cvD was 153 
seen in a monomeric form under non-reducing condition. VLPs were expressed in a 154 
similar fashion and purified as shown in Fig 1C. SDS-PAGE and western blot 155 
analysis confirmed the presence of dimeric E in VLP-cvD (~110 kDa) when analysed 156 
under non-reducing conditions, and this was reduced to a monomer in the presence 157 
of DTT (Fig 1D). We also observed two additional minor bands: one in the non-158 
reducing gel where a higher molecular weight protein possibly representing a more 159 
complex aggregate of E, and an approximately 90 kDa protein in the reducing gel 160 
which is likely an intermediate product resulting from an incomplete thiol reduction. In 161 
contrast, monomeric E (~55 kDa) was found in the VLP-WT preparation under both 162 
reducing and non-reducing conditions. The molecular weight of E in the VLP 163 
preparations was higher than that of the two sE proteins (Fig 1B) on account of the 164 
presence of the stem and anchor sequences. As expected, the viral M (10 kDa) was 165 
also detected in both forms of VLPs. Protein M is the product of furin-mediated 166 
cleavage of prM (25 kDa) during maturation of virus particles. The presence of M 167 
protein in the absence of prM suggested that in VLP-cvD the mutated glycoprotein 168 
underwent a complete maturation process during its synthesis, yielding smooth 169 
particles bearing the cvD E protein. Instead, the VLP-WT preparation contained 170 
residual prM implying that they were not fully matured (Fig 1E). Electron micrographs 171 
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(Fig 1F) of both types of VLPs showed particles of around 50 nm comparable to the 172 
size of infectious ZIKV particles (29).  173 
 174 
Antibodies generated by cvD immunogens are conformation-sensitive:  ZIKV 175 
cannot infect immuno-competent mice due to its inability to counteract murine 176 
interferon response (30). We therefore used the interferon receptor-deficient 177 
transgenic knock-out (Ifnar1-/-) A129 mice, which are susceptible to ZIKV infection 178 
and which have been shown to be amenable to vaccine evaluation studies (31). A 179 
cohort each of 4 weeks-old mixed male and female animals (n=6) were vaccinated 180 
with sE-WT, sE-cvD, VLP-WT, VLP-cvD, or PBS (as control). Three doses of 10 µg 181 
(sEs) or 2 µg (VLPs) of protein adjuvanted with ALUM (1%) combined with MPLA (5 182 
µg) were administered by sub-cutaneous route as shown in Fig 2A. One week after 183 
the last dose, blood samples were tested for the presence of anti-E antibodies.  184 
We first tested the serum antibodies for binding to biotinylated derivatives of ZIKV sE 185 
proteins fused in-frame with the Biotin-Acceptor Peptide (BAP). Specifically, 186 
recombinant sE-WT-BAP (monomer) or sE-cvD-BAP (dimer) co-expressed with the 187 
bacterial biotin ligase BirA (32, 33) (to allow in vivo mono-biotinylation) were used to 188 
quantify the titre of antibodies recognizing E in its monomeric or dimeric form.  189 
A comparison of the binding levels showed that sE-cvD immunisation elicited 190 
antibodies titres against the dimer four times higher than those obtained with sE-WT. 191 
On the other hand, analysis of the sera from VLP-WT- and VLP-cvD-vaccinated 192 
animals by ELISA showed no significant changes in the levels of antibodies (Fig 2C). 193 
It should be noted that this ELISA format is not robust enough to discriminate 194 
antibodies binding to more complex epitopes. 195 
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In order to further characterise the types of antibodies elicited by our cvD antigens, 196 
we used a recently developed cytofluorimetry assay of cells displaying dimers of 197 
ZIKV sE protein (paper in submission). In this assay, the C-terminus of sE is fused to 198 
the trans-membrane and cytosolic tail of the type-I trans-membrane protein MHC-Iα 199 
for plasma membrane display of the protein, as previously reported (28). This assay 200 
has the potential to discriminate antibodies binding exclusively to dimeric E on the 201 
basis of the pH-dependent mobility of E protein: at pH7, that resembles the neutral 202 
extracellular environment, the protein is in a dimeric conformation but at pH6, 203 
mimicking the conformational changes that occur in the acidic endosome vesicles 204 
during infection, it moves to a pre-fusion monomeric conformation. When exposed to 205 
a neutral pH (pH7), E can physiologically dimerize, and therefore be recognized by 206 
the dimer specific monoclonal antibody EDE 1C10 (24). However, this interaction is 207 
completely abrogated when cells are exposed to a lower pH (pH6), due to the 208 
disruption of the dimer. Thus, with this dimer-specific antibody two populations of 209 
cells can be detected by flow cytometry – antibody-bound and unbound – depending 210 
on the assay conditions (Fig 3A - EDE). On the other hand, antibodies binding to 211 
epitopes that do not require dimeric conformation of the protein are poorly affected 212 
by the pH and therefore show no differences in the binding capacity, as shown using 213 
in-house made monoclonal antibody DIII-1B (Fig 3A – DIII-1B), that recognizes a 214 
linear epitope located on domain III (Figs 3E and F). This assay is primarily 215 
designed, and indeed works optimally, for monoclonal antibodies. Nevertheless, we 216 
reasoned that it would still be useful in evaluating the nature of antibodies in sera 217 
from vaccinees containing a mix of IgGs capable of binding to linear or 218 
conformational epitopes. As shown in Figs 3B to 3D, serum antibodies from sE-WT- 219 
and VLP-WT-immunized groups seemed to not be particularly affected in the binding 220 
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by the pH-dependent change of conformation. In contrast, sera from sE-cvD- and 221 
VLP-cvD-vaccinated animals showed a more consistent pH-dependent difference in 222 
the relative peak positions (Fig 3B to 3D).  223 
Taken together, the data suggest that cvD antigens elicited a population of 224 
antibodies more sensitive to changes in conformation then the one elicited by the 225 
WT immunisation.  226 
 227 
cvD antigens elicit neutralizing antibodies in mice: A new immunisation was 228 
performed using the same procedure shown in Fig 2A. Antibody titres were 229 
measured using exclusively the sE-cvD-BAP ELISA (Fig 4A). The neutralizing 230 
capacity of these sera was then determined in a micro-neutralization (MN) assay that 231 
we had previously developed (9). This sandwich ELISA accurately measures the 232 
levels of glycoprotein E in infected cells thus enabling quantitation of virus infectivity. 233 
Vero cells were infected with the Puerto Rican ZIKV strain PRVABC59 (an Asian 234 
lineage isolate) that had been pre-incubated for 1 hour with serially diluted mouse 235 
sera. Three days post-infection the level of cellular E protein was determined by 236 
sandwich ELISA. Percentage of infectivity was calculated relative to E yield in cells 237 
infected in absence of sera. As shown in Fig 4B, antibodies elicited by sE-cvD and 238 
VLP-cvD significantly neutralized virus infection compared to sera from control 239 
group. VLP-cvD sera neutralized more strongly than sE-WT sera. Although not 240 
statistically significant, we observed a trend towards higher in vitro neutralization 241 













cvD immunogens protect mice from ZIKV challenge: To assess in vivo efficacy of 244 
our candidate vaccines, we challenged the above immunized animals with 104 pfu of 245 
ZIKV PRVABC59 by subcutaneous injection as shown in Fig 5A.   ,  A scoring 246 
system was used to monitor the progress of the disease, based on severity of clinical 247 
signs and symptoms, as described in Fig 5D. A score of 3 was considered as the 248 
humane endpoint. Animals were monitored for 9 days for their body weight changes 249 
(Fig 5C) and clinical signs (Fig 5E). The PBS control group began losing weight at 4 250 
days post-challenge (dpc) and subsequently exhibited clinical signs of infection and 251 
were euthanized at 7-8 dpc (Figs. 5B and C, grey lines). The sE-WT group lost less 252 
weight but exhibited clinical signs comparable to those seen in the PBS control 253 
group albeit with delayed kinetics (Figs. 5B and C, orange lines). One mouse of the 254 
sE-WT group succumbed to infection. A similar profile of weight change, clinical 255 
scores and survival were observed in VLP-WT group (Figs. 5B and C red lines) 256 
compared to the sE-WT group. Importantly, all animals immunised with cvD antigens 257 
survived the challenge, maintained a more stable weight profile and showed rapid 258 
recovery from the clinical signs of infection (Figs. 5B and C, purple and blue lines). 259 
Viremia was determined by RT-qPCR on blood samples taken at days 2, 3, 4 and 7 260 
during the course of the challenge (Figs. 6A and B). Since the limit of the assay was 261 
determined as a titre of 102 pfu equivalent/mL, for statistical analysis this value was 262 
given to all the samples that were below the limit of detection. As expected, PBS 263 
control mice showed very high viremia (>106 pfu/mL) which peaked at 3 dpc. In 264 
contrast, in all vaccinated animals the viremia peaked at 4 dpc, although the levels 265 
varied. Specifically, the sE-WT-vaccinated animals displayed levels comparable to 266 
those observed in the PBS control group (>105 pfu equivalent/mL). Instead, 267 
consistent reduction in viremia levels was observed in VLP-WT-, sE-cvD- and VLP-268 
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cvD-vaccinated animals which in the latter two groups was significant. In particular, 269 
the geometric mean of viral titre of 4×102 pfu equivalent/mL was the lowest in VLP-270 
cvD-vaccinated group. Relative organ viral load was analysed by RT-qPCR of viral 271 
RNA extracted from brain, spleen and sex organs, which were collected immediately 272 
after euthanasia (Fig 6C). ΔΔCT method was used to calculate the titre relative to an 273 
average of PBS control group. Although all four antigens reduced brain viral load, 274 
only cvD antigens reduced that of the sex organs. In case of spleen viral 275 
transmission, sE-cvD and VLP-cvD were better than sE-WT and control group 276 
whereas VLP-WT was only better than control group. All together, these data 277 
confirmed the unsuitability of wild-type antigens (especially sE-WT) whereas both 278 
cvD derivatives conferred full protection against ZIKV infection in vivo. 279 
 280 
cvD reduces in vitro ADE: Due to the close relationship with DENV and other 281 
mosquito-borne flaviviruses, a ZIKV vaccine is very likely to elicit cross-reactive 282 
antibodies that may fail in neutralizing other flavivirus infection and instead lead to a 283 
worse disease outcome. Our candidate vaccines are designed in order to reduce this 284 
risk, limiting exposure of highly cross-reactive but low cross-neutralising epitopes in 285 
favour of broadly neutralizing ones. We performed an in vitro ADE assays using the 286 
K562 monocyte cell line that expresses the Fcγ-receptor. Infection of these cells 287 
doesn’t occur through the normal entry pathway. Rather, it occurs exclusively via 288 
Fcγ-receptor-mediated internalization of the antibody-bound virus. In keeping with 289 
this, we observed an extremely low infection rate in absence of antibodies binding to 290 
the virus, i.e. when the virus was pre-incubated in the absence of serum (data not 291 
shown) or in the presence of the sera from our PBS-injected mice. Viruses pre-292 
incubated with ten-fold serial dilutions of the sera were added to the cells, incubated 293 
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for three days, and then analysed to determine the percentage of infection by 294 
cytofluorimetry. Experiment was performed in triplicate. (Fig 7).  295 
We used ZIKV as a control in the assay. As expected, pre-incubation with all the 296 
sera gave the same pattern of infection, suggesting that antibodies (neutralizing or 297 
otherwise) in the four groups of sera bind to ZIKV similarly to mediate infection. This 298 
is not surprising, since internalization occurs independently of the normal receptors 299 
and therefore the neutralizing antibodies are no longer capable of blocking entry. 300 
When tested against the four DENV serotypes, YFV and WNV, sera from the sE-WT 301 
immunized group conferred infection of between 50% and 100% of cells. Instead, 10 302 
times lower levels of infection were observed with sE-cvD sera, suggesting the 303 
presence of a much lower level of cross-reacting antibodies in these sera. Similarly, 304 
sera from VLP-cvD-immunised mice exhibited a 10-fold reduced infectivity compared 305 
to sera from VLP-WT animals. Particularly interesting was the level of infected cells 306 
obtained after virus incubation with VLP-WT sera, which was significantly higher than 307 
the infection obtained following incubation of the virus with the sera from sE-cVD and 308 
VLP-cvD immunised animals. These results suggest that the covalent dimer-based E 309 
vaccines (both, sE-cvD and VLP-cvD) confer a lower risk of ADE in comparison to 310 
their WT counterparts as determined by this experimental model. 311 
 312 
VLP-cvD protection coverage includes ZIKV African lineage: ZIKV has diverged 313 
decades ago into two lineages, the African and the Asian. Where the Asian lineage 314 
is responsible for the last epidemics and is linked to neurological outcomes and birth-315 
defects, the African lineage is -intriguingly- well known to be more pathogenic in in 316 
vivo models (34). Since a safe ZIKV vaccine should guarantee coverage of both 317 
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African and Asian lineages, we tested the VLP-cvD protectivity upon infection with a 318 
Ugandan (MP1751) isolate of ZIKV. Immunization and challenge were performed as 319 
previously described (Figs 2A and 5A). The PBS group lost weight starting from day 320 
3 post-challenge and all mice reached the endpoint at day 6 (Figs 8A and B, grey 321 
lines. Fig 8C). VLP-cvD-vaccinated group instead showed a stable body weight and 322 
all animal survived the challenge (Figs 8A and B, blue lines. Fig 8C). PBS-323 
immunised-control mice showed high peak of viremia (>107 pfu/mL) at 4 dpc while 324 
the vaccinated mice showed a highly significant reduction in viremia (~102 pfu/mL) 325 
(Fig 8D). Also, virus dissemination to the brain was suppressed in the VLP-cvD 326 
immunized mice (Fig 8E). All together, these results confirm the broadly protective 327 
potential of our vaccine candidate.   328 
 329 
Discussion 330 
Monoclonal antibodies recognizing quaternary epitopes that span on more than one 331 
E protein are reported to be the most neutralizing and cross-reactive class of 332 
antibodies (24, 35, 36). Nevertheless, they constitute only a minority of the 333 
antibodies elicited by a natural infection, where the larger response focuses on 334 
poorly neutralizing and cross-reactive epitopes located on DI/DII (15, 37). The 335 
incomplete maturation of particles and the mobility of E reduce their exposure, 336 
especially to dimeric epitopes, in favour of the Fusion-Loop epitope. However, our 337 
vaccines are designed in order to lock E in a dimeric conformation, impairing its 338 
disassembly and forcing the protein to display the desired epitopes.  339 
 340 
E-homodimer stability was proved several times to be affected by temperature: 341 
dimerization is favoured at 28˚C and reduced at 37°C, hence physiological 342 
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temperature is another element that contributes to impair dimers exposure to the 343 
immune system (38). But 28˚C is also a crucial temperature for expression and 344 
secretion of E protein, both in the soluble form but also as part of VLPs (28). Since 345 
this temperature is not compatible with genetic vaccination approaches, in which 346 
DNA or RNA encoding the antigen is administered and the antigen is then produced 347 
by the host cells at physiological temperature, the full potential of our antigens as 348 
candidate vaccines was evaluated in a protein-based vaccination approach. 349 
 350 
Recently, a characterization of two dimeric E antigens was published, dimerization 351 
was achieved by the A264C mutation or replacing the E transmembrane domain with 352 
the FC fragment of a human IgG (39). While this manuscript was under preparation, 353 
two other articles reported development and evaluation of dimer-based subunit 354 
vaccines similar to that described in here (40, 41). The authors showed that in all 355 
three cases the antigens were able to induce in mice the production of neutralizing 356 
antibodies. However, our work is the first application of E covalent dimers to virus-357 
like particles that proved in our hands to be a vaccine candidate superior to the 358 
soluble dimer.  359 
 360 
We tested the potential of E covalent-dimers when expressed in the form of soluble 361 
protein, lacking the stem-anchor, and also as VLP. In comparison with sE-WT we 362 
observed a dramatic effect of the cvD mutation on the immune response, with a 363 
drastic reduction of antibodies binding to monomeric E and an impressive increase in 364 
protective activity upon lethal challenge. When the comparison was performed with 365 
the VLPs, the effect was less dramatic in terms of anti-dimer antibody titres. This is 366 
likely due to the thermal stability of dimers that is higher in ZIKV than in DENV (42), 367 
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ZIKV E dimers are more stable, as already proven by the necessity of a double 368 
disulphide bridge to lock DENV E dimer when one bridge is sufficient in ZIKV E. In 369 
addition, our ELISA and binding assays are based on E subunits presented in a 370 
monomeric or dimeric form but cannot fully recreate the complex symmetry of E 371 
protein on the viral particles therefore cannot quantify the contribution of antibodies 372 
binding to adjacent dimers. However, the difference in antibody response and 373 
protectivity was enough to achieve an important reduction in DENV ADE. In this 374 
regard it is noteworthy that the VLP-cvD lacked prM indicating their complete 375 
maturation. In contrast, VLP-WT contained prM that can elicit anti-prM antibodies 376 
upon vaccination. The prM protein is naturally present in DENV or ZIKV particles, 377 
due to incomplete maturation, but prM antibodies from DENV patients showed no or 378 
poor neutralizing activity and may instead likely induce ADE (43). All together these 379 
observations strongly suggest that covalently linked E dimer can bring even higher 380 
benefits to the development of a DENV vaccine. 381 
 382 
The development of a ZIKV vaccine requires attention to the possible cross-reaction 383 
with DENV. ADE of infection between different DENV serotypes is widely recognised 384 
as the cause of dengue shock syndrome (DSS) but the role that ZIKV infection may 385 
play at any point in influencing DENV infections is still unclear. Unfortunately, it is not 386 
easy to experimentally predict ADE, since results obtained from in vitro and in vivo 387 
settings, and those from among different in vivo models are not always consistent. 388 
So far animal models have not been able to replicate the full repertoire of the 389 
antibody response in humans. In addition, it is difficult to reproduce severe DENV 390 
infection in animal models; in most cases the severity of infection is based on 391 
increased viremia in the infected animals. In vitro tests performed with DENV-392 
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positive sera or DENV monoclonal antibodies showed cross-reactivity and ADE of 393 
ZIKV infection, similar to experiments performed in mouse models (20, 44-46). 394 
Conversely, analysis performed in non-human primate models ruled out a negative 395 
effect of previous DENV exposure on ZIKV infection (47), which was later confirmed 396 
by population studies with asymptomatic ZIKV infection in subjects positive for DENV 397 
antibodies (48). Concerns of cross-reaction and ADE were also raised about 398 
vaccination against other flaviviruses. In vitro studies supported negligible risk of 399 
ADE of ZIKV after tick-borne encephalitis virus vaccination and no clinical evidence 400 
of increased disease severity in vaccinated people has emerged so far (49). The fear 401 
of predisposing vaccinated individual to DSS generated a reluctance to deploy the 402 
YFV vaccine in DENV endemic areas, but a recent long-term study showed no 403 
evidence of increased risk (50). Not much is known about the role of WNV antibodies 404 
in causing other flavivirus ADE and vice versa. Like DENV, sera from WNV patients 405 
exhibit in vitro ADE of ZIKV (45). However, while DENV ADE is a well-documented 406 
phenomenon, to our knowledge there is as yet no evidence of ADE occurring 407 
between DENV/ZIKV and WNV in humans.  408 
However, the sequence homology between ZIKV and DENV is high with elevated 409 
antibody cross-reactivity (15, 20). According to a recent publication, ZIKV infection 410 
can increase risk of a severe DENV2 disease at the same level as a previous 411 
heterologous dengue infection (51) and therefore how ZIKV vaccination can affect 412 
DENV pathogenesis is a pertinent question that remains to be addressed.  413 
 414 
We evaluated the ADE potential (on DENV, YFV and WNV) of the different sera 415 
using K562 cells. These cells express high levels of FcγRIIA and significantly favour 416 
FcγR-mediated infection, making them suitable for studying ADE in an in vitro 417 
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setting. We found that sera from sE-WT-immunised animals exhibited high ADE in 418 
our assay presumably because the antigen exposes well known conserved epitopes, 419 
such as the FLE, allowing high level of cross-reactivity. In contrast, ADE was 420 
strongly reduced when E was locked in the dimeric form (sE-cvD) and properly 421 
folded, likely because  conserved but poorly neutralising epitopes on DI/DII are not 422 
exposed. We obtained interesting results upon comparison of sera from mice 423 
immunised with VLPs bearing a WT or a cvD form of the full-length ZIKV E 424 
glycoprotein. While the VLP-WT conferred protection from lethal infection in mice, 425 
the sera from the same immunised animals induced in vitro ADE of ZIKV at levels 426 
comparable to sE-WT-immunised sera, or even higher as in the case of DENV1 and 427 
DENV4. In contrast, and as with sE-CvD, sera from VLP-cvD-immunised animals 428 
exhibited strongly reduced ADE of the flavivirus under analysis. This raises safety 429 
concerns about a vaccine that, despite protecting from ZIKV infection, may bring 430 
more adverse effects on subsequent DENV infections. Once again, this risk is 431 
reduced with the VLP-cvD antigen. However, to what extent ADE in vitro mimics any 432 
in vivo effects remains to be determined. 433 
 434 
ADE of DENV upon ZIKV immunisation is a risk that cannot be underestimated. One 435 
way to reduce antibody cross-reactivity would be to focus on developing a less 436 
conserved subunit vaccine, like DIII. However, we recently showed that this 437 
approach fails in protecting from in vivo challenges(52). The development of 438 
engineered, safe vaccine is probably an essential requirement to tackle this 439 
concerning public health challenge. Our two immunogens proved the high potential 440 
of engineered E protein locked in a dimeric conformation as a suitable vaccine 441 
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candidate, with the most promising results achieved when the protein is part of a 442 
structurally more complex antigen presented in the form of a virus-like particle. 443 
 444 
Material and Methods 445 
Cell lines and virus strains: Expi293F (Thermo Fisher Scientific) embryonic human 446 
kidney adapted to serum-free conditions) cells were grown in Expi293™ Expression 447 
Medium as per the manufacturers’ protocol. Vero E6 cells were grown in Dulbecco's 448 
Modified Eagle's Medium (DMEM) (Life Technologies) containing 10% fetal bovine 449 
serum (FBS) (Life Technologies) and penicillin-streptomycin (Gibco), K562 cells 450 
were grown in Roswell Park Memorial Institute (RPMI) 1640 medium (Life 451 
Technologies) containing 10% Fetal Bovine Serum (FBS) (Life Technologies). ZIKV 452 
PRVABC59 (kindly supplied by BEI Resources; Accession Number KX087101) and 453 
ZIKV MP1751 (005V-02871; kindly supplied by Public Health England: Accession 454 
Number KY288905.1) were used for infection experiments, micro-neutralisation and 455 
animal challenge. 456 
 457 
Plasmid DNA constructs: ZIKV sE-encoding sequence (codon 1-404) was 458 
amplified from ArD158095 strain (Accession number KF383121.1) as described in 459 
Sloan Campos et al(28). sE fused to a N-terminal immunoglobulin leader sequence 460 
(sec) and a C-terminal V5 tag (GKPIPNPLLFLD) was cloned into a pVax vector. A 461 
mammalian codon-optimized ZIKV prME gene sequence, flanked by the C-terminal 462 
portion of C and the N-terminal reside of NS1, was obtained from ZIKV PE243 463 
Brazilian strain (Accession number KX197192.1(53)) (aa 105-815 of the polyprotein) 464 
and cloned into a pDIs vector. The A264C mutation was introduced by site-directed 465 
mutagenesis into both plasmids. 466 
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Protein expression and purification: sE-WT, sE-cvD, VLP-WT and VLP-cvD were 468 
expressed using ExpiFectamine™ 293 Transfection Kit (Thermo Fisher Scientific) 469 
following manufacturer’s instructions. After 16 hours, cells were moved to 28°C. At 5 470 
days post-transfection the supernatant was harvested and filtered. sE proteins were 471 
purified using the V5-tagged Protein Purification Gel (Caltag Medsystems Ltd) 472 
eluting with 2 mg/mL of V5 peptide. VLPs, they were pelleted down by 473 
ultracentrifugation (115,000 g, 4C, 2 hours) (Sorvall discovery 90SE with 474 
Surespin630 rotor) through a cushion of 20% sucrose in TN Buffer (20 mM Tris and 475 
120 mM NaCl). The pellet was re-suspended in TN buffer and loaded on 476 
discontinuous density gradient made by sodium potassium tartrate and glycerol in 477 
TN buffer (29). Tartrate concentration ranged from 10 to 30% with interval of 5% 478 
whilst that of glycerol ranged from 7.5 to 22.5% with interval of 3.75%. After 479 
centrifugation (Sorvall discovery 90SE with TH641 rotor) at 175,000 g, 4C, 2 hours, 480 
fractions were collected and analysed for the presence of ZIKV E by western lot. 481 
ZIKV E protein-positive fractions were pooled, dialysed against Dulbecco’s 482 
phosphate-buffered saline (DPBS) (Life Technologies) and concentrated using spin 483 
column (Amicon® Ultra-15 (100 kDa), Merck Millipore) before being subjected to 484 
size-exclusion chromatography. Briefly, ~500 µL of concentrated pooled fractions 485 
was loaded onto HiPrep 16/60 Sephacryl S-500 HR column (GE Healthcare) then 486 
1.5 column volume of mobile phase (DPBS) was run through the column at flow rate 487 
of 0.5 mL/min using the AKTA Pure (GE Healthcare) system. Fractions were 488 
collected and tested for ZIKV E protein. Positive fractions were pooled and 489 
concentrated using the Amicon® Ultra-15 (100 kDa; Merck Millipore) spin column. 490 
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The concentration of the purified proteins was determined using NanodropOne 491 
(ThermoScietific). 492 
 493 
SDS-PAGE and western blot: sE samples were subjected to 10% SDS-PAGE, and 494 
the fractionated proteins detected by direct staining of the gel with InstantBlue 495 
(Sigma) or by western blot. VLP samples were separated by 10% or 14% SDS-496 
PAGE later blotted to PVDF membrane (Immobilon®-FL, Merck Millipore) and 497 
blocked overnight with ODYSSEY® blocking buffer, LI-COR then incubated DIII1B 498 
antibody (anti-ZIKV E DIII generated in-house as described in Figure 3) or ZIKA prM 499 
antibody (GeneTex) for 1 hour followed by anti-mouse IgG (IRDye® 800CW, LI-500 
COR) and anti-rabbit IgG (IRDye® 680RD, LI-COR). Images were acquired by 501 
LICOR machine.  502 
 503 
Electron microscopy: VLPs were adsorbed for 3 min to Formvar carbon films 504 
mounted on 400 mesh per inch copper grids (Agar Scientific). Samples were washed 505 
three times with distilled water and stained with 2% saturated uranylacetate (Agar 506 
Scientific) for 2 min at room temperature. Specimens were analysed in a 507 
transmission electron microscope (JEM-1200 EX II, JEOL) equipped with a CCD 508 
camera (Orius, Gatan) at an acceleration voltage of 80 kV. 509 
 510 
Animal immunisation: Four-week old male and female Ifnar1-/- mice (A129, 129S7 511 
background; Marshall BioResources) (n=6) were subcutaneously immunised with 512 
ZIKV antigen formulated in aluminium hydroxide gel (1% ALUM, Brenntag) combined 513 
with 5 µg monophosphoryl lipid A (MPLA)(InvivoGen) or PBS containing the 514 
adjuvant. Purified sE antigens used in each immunisation contained 10 µg protein 515 
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whilst it was 2 µg in case of VLPs. Mice were immunised at 0, 2 and 3 weeks and 516 
bled 4 weeks after primary immunisation for antibody titration and micro-517 
neutralisation assay. Four weeks after primary immunisation, mice were challenged 518 
subcutaneously with 104 pfu of Puerto Rican ZIKV (PRVABC59) or Uganda ZIKV 519 
(MP1751). Blood was collected at 2, 3, 4 and 7 dpc and 10 µL of sera were 520 
assessed by RT-qPCR. Mice were euthanised when they exhibited three or more 521 
signs of moderate severity or lost more than 15% body weight, otherwise 9/10 days 522 
after challenge.  523 
 524 
Animal Ethics 525 
All animal research described in this study was approved by the University of 526 
Glasgow Animal Welfare and Ethical Board and was carried out under United 527 
Kingdom Home Office Licenses, P9722FD8E, in accordance with the approved 528 
guidelines and under the UK Home Office Animals (Scientific Procedures) Act 1986 529 
(ASPA). 530 
 531 
ELISA: Recombinant biotinylated proteins (sE, sE-cvD and DIII) were expressed at 532 
28°C using ExpiFectamine™ 293 Transfection Kit (Thermo Fisher Scientific). Cell 533 
supernatant was harvested and dialyzed. Biotinylated proteins were captured in 534 
ELISA plates pre-coated with 5 µg/mL of Avidin (Sigma) in Na2CO3/NaHCO3 buffer 535 
pH 9.6, subsequently blocked with PBS containing 0.05% Tween-20 and 1% bovine 536 
serum albumin (BSA-Sigma). Serial dilutions of mouse sera were tested for binding 537 
to the biotinylated proteins and the bound antibodies detected using HRP-conjugated 538 













Antibody binding assay: This assay was performed as previously described in 541 
(paper in submission). HEK cells stably expressing ZIKV sE protein on the surface 542 
were blocked in 1% BSA in PBS at pH 6 or 7 and then incubated with mouse sera 543 
diluted 1:500 in the same solution. After wash, cells were incubated with secondary 544 
anti-mouse Alexa 488 (Jackson Immunoresearch) 1:50000 in 1% BSA PBS pH 7 545 
and analysed by cytofluorimetry in a FACSCalibur (BD Biosciences). 546 
 547 
Micro-neutralisation (MN) assay: This assay was performed as described in 548 
Lopez-Camacho et al (9). Briefly, 7 × 103/well of Vero cells were seeded in 96-well 549 
plates and incubated at 37 °C in 5% CO2. Next day, three-fold serially diluted mice 550 
sera were first incubated at 37°C for 1 hour with 100 pfu/well ZIKV strain 551 
PRVABC57. The serum/virus mix was then used to infect cells. After 1 hour of 552 
incubation at 37 °C, 100 µL of medium was added to each well. At day 3 post-553 
infection, cells were lysed in lysis buffer (20 mM Tris-HCl [pH 7.4], 20 mM 554 
iodoacetamide, 150 mM NaCl, 1 mM EDTA, 0.5% Triton X-100 and Complete 555 
protease inhibitors) and the viral E protein quantitated by sandwich ELISA (see 556 
below). The amount of E protein detected correlates with the level of virus infectivity 557 
which was presented as % of ZIKV infectivity relative to the control (i.e., virus not 558 
pre-incubated with immune sera). The MN50 titre was defined as the serum dilution 559 
that neutralised ZIKV infection by 50%. 560 
 561 
Sandwich ELISA to assess ZIKV infectivity: ELISA plates were coated with 3 562 
μg/mL of purified pan-flavivirus MAb D1-4G2-4-15 (ATCC® HB112TM) in PBS and 563 
incubated overnight at RT and subsequently blocked for 2 hours at RT with PBS 564 
containing 0.05% Tween-20 and 2% skimmed milk powder. After washing with 565 
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PBST, ZIKV-infected cell lysates were added and incubated for 1 hour at RT. Wells 566 
were washed with PBST, incubated with anti-ZIKV E polyclonal R34 IgG (9)  at 6 567 
μg/ml in PBST for 1 hour at RT and washed again. Antibodies bound to ZIKV 568 
envelope protein were detected using HRP conjugate anti-rabbit IgG 7090 (Abcam) 569 
and TMB substrate (Life Technologies).  570 
 571 
Quantitation of viral RNA by RT-qPCR: Viral RNA was extracted from 10 µL of 572 
mouse sera using QIAamp® viral RNA Mini Kit (Qiagen) or about 20 mg of organs 573 
homogenised by Precellys Lysing Kit Hard tissue grinding (Bertin Technologies) 574 
using RNeasy viral mini kit. The viral load was measured by RT-qPCR using One-575 
Step SYBR® Primescript™ RT-PCR kit II (Takara). CT values of serum samples 576 
were used to calculate serum viral titre according to regression equation built by 577 
RNA extracted from 10 µL of 102-106 pfu/mL of ZIKV (PRVABC59 or MP1751). In 578 
case of relative organ viral load, CT values of ZIKV gene and internal control B2M 579 
gene were used for calculating ΔCT values. Average ΔCT of PBS-injected mice was 580 
used as reference to calculate ΔΔCT value. Primers pair for PRVABC59 ZIKV gene 581 
was Forward:5’-GTTGTCGCTGCTGAAATGGA-3’ and Reverse:5’-582 
GGGGACTCTGATTGGCTGTA-3’. Primers pair for MP1751 ZIKV gene was 583 
Forward:5’-ACTTCCGGTGCGTTACATGA-3’ and Reverse:5’-584 
GGGCTTCATCCATGATGTAG-3’. Primers pair for the B2M genes was Forward: 5’-585 
CGGCCTGTATGCTATCCAGA-3’ Reverse: 5’- GGGTGAATTCAGTGTGAGCC -3’. 586 
 587 
ADE assay: Ten-fold serial dilutions of pooled sera were mixed with 4x103 pfu of 588 
each virus and incubated for 1.5 hour at 37 °C before mixing with 4x104 K562 cells. 589 
After incubation at 37°C for 2 days (for WNV) or 3 days (all other viruses), cells were 590 
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fixed with 2% PFA for 30 min and then washed in PBS. Blocking and 591 
permeabilization buffer (0.1% saponine, 2 % FBS, 0.1% NaN3 in PBS) was added to 592 
cell for 30 min at 4 °C. Cells are incubated with mAb 4G2 (1 µg/mL) for 1hour at 4 °C 593 
followed by secondary anti-mouse Alexa 488 (Jackson Immunoresearch, 1:50000). 594 
After washing with PBS, cells are re-suspended in blocking buffer without saponine 595 
and analysed by cytofluorimetry in a FACSCalibur (BD Biosciences).  596 
 597 
Statistical analysis: Normality was determined by Ryan-Joiner Normality test with 598 
Minitab Software. Statistical analysis was done as indicated in figure legends, with 599 
Minitab or GraphPad Prims softwares. *p<0.05, **p<0.01, ***p<0.001. Where 600 
asterisks are missing the differences are calculated as nonsignificant (ns). 601 
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Figure Legends 829 
 830 
Figure 1: Expression, purification and characterisation of ZIKV E antigens.  (A) 831 
Schematics of the genetic constructs used to express SV5-tagged ZIKV sE (amino 832 
acid or aa 1 – 404) in the WT or cvD (carrying A264C mutation) form. Expi293F cells 833 
were transiently transfected with the relevant constructs and the expressed proteins 834 
secreted into the medium were purified using V5-tag affinity chromatography. (B) 835 
SDS-PAGE of the purified protein. sE-WT and sE-cvD were analysed in SDS-836 
PAGE run in presence or absence of reducing conditions. Black arrows show 837 
monomers of sE, blue arrows show dimers. (C) Schematics of VLP antigens 838 
design and purification: Plasmid constructs carrying the sequences encoding the 839 
capsid anchor (i.e. the N-terminal 18 amino acids of Capsid protein), followed by prM 840 
and full-length E genes, the latter in its WT form or in the form of cvD (i.e. carrying 841 
the A264C mutation). The constructs were transiently transfected in Expi293F cells 842 
and the secreted VLPs were pelleted by sucrose cushion 4 days post-transfection 843 
and subsequently purified by density gradient followed by size-exclusion 844 
chromatography (SEC). (D) Western Blot of the purified VLPs showing dimeric 845 
conformation: Purified VLP-WT and VLP-cvD were analysed by SDS-PAGE under 846 
reducing or non-reducing conditions E was detected using in-house made 847 
monoclonal antibody DIII-1B. Black arrows show E monomers; blue arrow shows 848 
dimers; grey arrows show higher order oligomers (non-reducing gel) or partially 849 
resolved complexes (reducing gel) of the E protein. (E) Western Blot of the purified 850 
VLPs showing prM and M content: Purified VLP-WT and VLP-cvD were analysed 851 
by SDS-PAGE (14% acrylamide) under reducing conditions. Protein E was detected 852 
using the monoclonal antibody DIII-1B (in green), whereas proteins prM and M were 853 
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detected using an anti-M antibody (in red). (F) Electron microscope picture of 854 
purified VLPs: Electron microscopy (uranyl acetate staining) of VLP-WT (left panel) 855 
and VLP-cvD (right panel) purified as described in (c). Bars indicate the diameter of 856 
the particles. 857 
 858 
Figure 2: (A) Schematic representation of the immunisation procedure: Five 859 
groups each (n=6) of 4 weeks-old mice received respectively sE-WT, sE-cvD, VLP-860 
WT, VLP-cvD or PBS, mixed with ALUM-MPLA adjuvant as shown. Following two 861 
boosts at weeks 2 and 3, test bleeds were collected at week 4 for analyses. (B and 862 
C) Anti-E antibody titres of sera collected from animals immunised with sE (B) 863 
or VLP proteins (C). Antibody titres were determined using ELISA plates coated 864 
with mono-biotinylated monomeric E, dimeric E and DIII. Ctrl: pooled sera from PBS 865 
control group. The titre was defined as the maximum dilution that gives a value 866 
higher than three-times the value given by the pre-immune sera. The control sera 867 
were negative at the lowest dilution (1:900) and their titre was calculated as 1/3 of 868 
that dilution (300). Statistical analysis was done using 2-sided ANOVA 95% 869 
confidence level with Tukey Pairwise comparison at 95% confidence (Minitab 870 
software). 871 
 872 
Figure 3: Determination of binding characteristics of serum IgGs to different 873 
sE conformations. Cells expressing sE on the cell surface were incubated with (A) 874 
pooled control sera (Control), monoclonal EDE antibody 1C10 (EDE), monoclonal 875 
DIII-1B antibody (DIII-1B) at pH 6.0 (red) or pH 7.0 (blue). Following washing, the 876 
bound antibodies were detected using a fluorescence-tagged secondary antibody 877 
and the relative fluorescence determined by flow cytometry using FACSCalibur. 878 
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Mean of fluorescence intensity was calculated using FlowJo software and plotted 879 
(fourth panel). (B and C) Sera from immunised animals were incubated with cells as 880 
described in A. (B) Histogram plots show data of one serum as representative of 881 
each immunised group. (C) Bar charts showing data of sera from individual animals 882 
from each immunised group plotted as mean of fluorescence intensity. D) Ratio 883 
between the intensity of fluorescence at different pH was calculated, grey column 884 
represent mean. Statistical analysis was done using one-way ANOVA 95% 885 
confidence level with Tukey’s multiple comparison (GraphPad software). Data are 886 
representative of three independent experiments, performed with pooled and single 887 
sera. Characterisation of the mouse monoclonal antibody (MAb) DIII-1B. MAb 888 
DIII-1B was obtained using standard hybridomas technology from Balb/c immunised 889 
with recombinant domain III of ZIKV E protein. The specificity of MAb DIII-1B was 890 
tested by (E) western immunoblotting of VERO cells that were mock-infected (-) or 891 
infected with ZIKV (+). As expected, MAb DIII-1B specifically bound to ZIKV E 892 
protein. Protein molecular weight ladder is shown on the left in kDa. Separately, the 893 
binding specificity of MAb DIII-1B was also tested by (F) indirect 894 
immunofluorescence of uninfected or ZIKV-infected A549-NPro cells. Green signal 895 
indicates antibody binding to ZIKV E protein. Cell nuclei were stained with DAPI 896 
(blue). 897 
 898 
Figure 4: Determination of anti-E or neutralising antibody titres of sera from 899 
vaccinated animals. (A) Anti-E titres: ELISA plates coated with biotinylated 900 
dimeric E were incubated with serially diluted serum samples and the bound 901 
antibodies detected as described in Materials and Methods. Antibody titres were 902 
determined as described in the Figure 2 legend. (B) Neutralisation of ZIKV 903 
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infection: Serially diluted samples of mouse sera were incubated with ZIKV for 1 904 
hour before infecting Vero cells. At 72 hours post-infection, the intracellular levels of 905 
E were determined by capture sandwich ELISA and percentage of infectivity relative 906 
to the virus alone infection was calculated. The results were plotted as MN50 values - 907 
i.e. titres at which 50% neutralisation was achieved. Statistical analysis was 908 
performed using 2-sided ANOVA 95% confidence level with Tukey Pairwise 909 
comparison at 95% confidence (Minitab software). Data from three independent 910 
experiments were used 911 
 912 
Figure 5: In vivo efficacy of candidate vaccines.  (A) Schematic representation 913 
of the in vivo challenge protocol: Mice were challenged with 104 pfu of ZIKV 914 
PRVABC59 one month after the primary immunisation and were monitored for up to 915 
9 days. Test bleeds (TB) and organs were collected as shown. Animals were 916 
weighed (C) and scored for clinical signs daily post-challenge with percentage 917 
of survival shown in (B). (D) Legend of scoring system used to monitor animal 918 
health following ZIKV challenge. (E) Table showing the score attributed to each 919 
animal after ZIKV PRVABC59 challenge. Animals displaying a weight loss of 15% or 920 
more were euthanised. All the member of the control group reached the endpoint 921 
score 7-8 days post-challenge and were therefore euthanised. Statistical analysis 922 
was performed using Log-Rank (Mantel-Cox test) with GraphPad Prism software. 923 
 924 
 Figure 6: Viral titre in challenged animals. (A) The levels of ZIKV in the serum 925 
at day 2, 3, 4 and 7 post-infection were quantified by RT-qPCR and the results 926 
plotted as pfu/ml. (B) The limit of detection was estimated to be 100 pfu/mL, 927 
indicated by the green line. Columns show mean of all mice. Statistical significance 928 
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is reported in the table. (C) Relative viral load in brain, spleen and sexual 929 
organs: The presence of viral RNA in tissues was quantified by RT-qPCR and the 930 
results plotted as relative viral load calculated on the average of the PBS control 931 
group. Statistical significance is reported in the table. Statistical analysis was done 932 
using 2-sided ANOVA 95% confidence level with Tukey Pairwise comparison at 95% 933 
confidence with Minitab software. 934 
 935 
Figure 7: Effect of pooled sera on ADE of infection by all four DENV serotypes 936 
1-4, ZIKV, WNV and YFV. Viruses were pre-incubated with 10-fold dilution of pooled 937 
sera for 1 hour before infecting K562 cells. Percentage of infected cells was 938 
calculated by cytofluorimetry. Control consists of pooled sera from PBS-injected 939 
mice. Statistical significance applies to the comparison between VLP-WT and sE-940 
cvD/VLP-cvD. Statistical analysis was done using 2-sided ANOVA 95% confidence 941 
level with Tukey Pairwise multiple comparison (GraphPad software). Experiments 942 
were performed in triplicate.  943 
 944 
Figure 8: (A) Survival rate of vaccinated animals upon ZIKV challenge: Mice 945 
were challenged with 104 pfu of ZIKV MP1751. All the member of the control group 946 
reached the endpoint score 6 days post-challenge and were therefore euthanised. 947 
Statistical analysis was performed using Log-Rank (Mantel-Cox test) with GraphPad 948 
Prism software. (B) Body weight variations after challenge: weight loss of mice 949 
after ZIKV infection. Animals showing a weight loss of 15% or higher were 950 
euthanised. (C) Clinical scores attributed to each animal after ZIKV MP1751 951 
challenge. (D) Viral load in serum: The presence of ZIKV in the serum at day 2, 3 952 
and 4 post-infection was quantified by RT-qPCR. Green line indicates the limit of 953 
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detection. (E) Relative viral load in brain: presence of viral RNA in tissues was 954 
quantified by RT-qPCR. Statistical analysis was done using 2 sided Two-Sample T-955 
Test 95% confidence level with Minitab software. 956 
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